Medicines Used in Right-Sided Hemiparesis and Left Hemisphere Brain Enhancement

Understanding the Anatomy First

• Right-sided motor and sensory function (via the corticospinal tract)
• Language and speech (Broca's area, Wernicke's area)
• Logical sequencing and analytical function

1. Treating the underlying cause (stroke, TBI, tumor)
2. Enhancing neuroplasticity - helping the left brain reorganize and recover
3. Managing spasticity - reducing muscle tone on the affected right side
4. Treating associated deficits - aphasia, depression, pain

Category 1: Neuroplasticity Enhancers (Enhance Left Brain Function)

A. SSRIs (Selective Serotonin Reuptake Inhibitors)

• A 2023 meta-analysis (PMID: 37205743) found SSRIs improved Fugl-Meyer Motor Scale and Barthel Index scores vs control in post-stroke recovery.
• However, a 2024 individual patient data meta-analysis of 5,907 patients (PMID: 38497332) found fluoxetine 20 mg for 6 months did NOT improve modified Rankin Scale at 6 or 12 months, and increased seizure risk, falls, fractures, and hyponatremia - though it did reduce post-stroke depression.
• Bottom line: SSRIs are appropriate for post-stroke depression (which itself impairs recovery), but their direct motor recovery benefit is now uncertain at the population level.

B. Levodopa

• Has been investigated in early post-stroke motor recovery via dopaminergic upregulation of motor cortex excitability.
• Some small RCTs showed modest benefit in motor and language recovery when combined with physiotherapy.
• Not yet standard of care; used in specialist centers.

C. Amphetamines (e.g., D-Amphetamine)

• Increase release of norepinephrine and dopamine, enhancing cortical arousal and synaptogenesis.
• Some evidence of accelerated motor recovery when given with physiotherapy, but inconsistent results and abuse potential limit use.
• Methylphenidate is preferred in TBI-related hemiparesis - used in clinical practice and noted in Kaplan & Sadock's: "Treatment with methylphenidate led to modest improvements in speed of information processing speed and apathy."

D. Cholinesterase Inhibitors (e.g., Donepezil, Rivastigmine)

• Enhance cholinergic transmission, improving attention, memory, and cortical activation.
• Useful when cognitive deficits accompany motor hemiparesis (e.g., in TBI or multi-infarct states).

Category 2: Anti-Spasticity Drugs (Reduce Right-Sided Muscle Tone)

A. Oral Agents

B. Local / Interventional

• Bradley and Daroff's Neurology in Clinical Practice notes: "The management of spasticity centers around reducing unwanted symptoms that limit quality of life. Treatment modalities include physical therapy and rehabilitation, pharmacological interventions (oral and intrathecal)."

Category 3: Neuroprotective / Acute Phase Agents

Category 4: Treating Left Hemisphere-Specific Deficits

Summary Table

Important Clinical Notes

1. No single drug "enhances left brain function" in a broad sense - recovery is multimodal. Pharmacotherapy is always combined with intensive physiotherapy, occupational therapy, and speech therapy for best results.
2. Fluoxetine's motor benefit is now questioned by large RCTs (FOCUS, AFFINITY, EFFECTS trials pooled in the 2024 IPDM). It should be used for depression, not routinely for motor recovery.
3. Botulinum toxin A is the strongest focal antispastic agent and works best when combined with rehabilitation (not alone).
4. Timing matters - neuroplasticity is greatest in the first 3-6 months post-injury; this is the window when pharmacological and rehabilitation interventions have maximum impact.
5. Epilepsy prophylaxis is not routine after stroke but is mandatory if a seizure occurs (left hemisphere cortical injuries are prone to post-stroke epilepsy).

Latest Research on Neuroplasticity-Enhancing Drugs in Stroke Recovery

The Core Challenge

Drug-by-Drug: Current Evidence (2023-2026)

1. SSRIs - Fluoxetine / Sertraline

Bottom line: SSRIs should be used for post-stroke depression only, not as a motor recovery enhancer. The fluoxetine story is essentially closed.

2. Levodopa (Dopaminergic Enhancement)

• Design: Multicenter, double-blind, placebo-controlled RCT across 13 stroke units in Switzerland
• Patients: 610 patients with acute ischemic or hemorrhagic stroke + clinically meaningful hemiparesis
• Intervention: Levodopa/carbidopa 100 mg/25 mg TID for 39 days + standardized rehabilitation
• Primary outcome: Fugl-Meyer Assessment total score at 3 months
• Result: Mean difference = -0.90 points (95% CI: -3.78 to +1.98; p = 0.54)

3. Cerebrolysin (BDNF-like Neuropeptide Mixture)

• Mechanism: Mimics BDNF/NGF signaling, promotes neuronal survival, dendritic sprouting, and synaptic plasticity
• Key findings: Significant improvement in daily activity when given during early comprehensive rehabilitation; significant improvement in upper limb function (ARAT scale); improved speech with concurrent speech therapy; reduced depression; improved social adaptation
• Optimal dose: 30 mL (higher doses outperform 10 mL doses)
• Timing: Best when started in early subacute phase; efficacy drops with late initiation or short courses
• Evidence base: 10 studies included - a modest evidence base, but results are consistent

Widely used in Eastern Europe and Asia; limited use in Western centers due to regulatory status.

4. Pharmacotherapy for Post-Stroke Cognitive Impairment

5. CCR5 Receptor Blocker - Maraviroc

• CCR5 is a chemokine receptor. Blocking it (with the HIV drug maraviroc) has been shown to enhance neural plasticity and functional recovery in preclinical stroke models
• Mechanism: CCR5 normally limits dendritic remodeling and axonal sprouting; blocking it releases this brake on plasticity
• A UCLA-linked team showed CCR5 deletion in mice promoted motor recovery and bilateral connectivity after stroke
• Small human case series showed striking functional recovery in stroke patients who coincidentally received maraviroc for HIV
• Status: Clinical trials underway - not yet standard of care

6. DDL-920 - UCLA's Parvalbumin Neuron Activator

• Discovery: Physical rehabilitation after stroke restores gamma oscillations in the brain - rhythmic activity generated by parvalbumin interneurons that links neurons into coordinated networks for movement
• Stroke destroys parvalbumin neuron connections and eliminates gamma oscillations
• DDL-920 - a novel small molecule that specifically excites parvalbumin neurons - fully reproduced the effects of physical rehabilitation in stroke mice, restoring gamma oscillations and producing significant motor recovery
• This is described as "the first drug to fully reproduce the effects of stroke rehabilitation"
• Next step: Safety and efficacy studies before human trials

This is a paradigm shift - targeting a specific neural rhythm mechanism rather than broadly boosting neurotransmitters.

7. Herbal / Phytochemical Agents

8. Chemogenetics - DREADDs

• Excitatory DREADDs (hM3Dq) in peri-infarct neurons: enhance neuroplasticity, axonal sprouting, and behavioral recovery
• Inhibitory DREADDs (hM4Di): suppress excitotoxicity and spreading depolarizations in the acute phase
• Phase-specific strategy: inhibit early (to reduce damage), excite late (to promote plasticity)
• Challenge: Requires viral vector delivery to the brain - not yet clinically translatable

Summary: Evidence Hierarchy (2026)

Key Takeaway for Clinical Practice (2026)

1. Treat post-stroke depression (SSRIs - proven to reduce depression and thereby improve recovery indirectly)
2. Cognitive enhancers (donepezil, memantine) for post-stroke cognitive impairment
3. Botulinum toxin A for focal spasticity combined with intensive rehab
4. Cerebrolysin (where available) initiated early in subacute rehabilitation